Cizzle Biotechnology Received U.S. Lab Accreditation
The company successfully validated its early-stage lung cancer blood test in the first half of 2026.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Would you regularly undergo a blood test if it could detect early-stage lung cancer?
In the first half of 2026, Cizzle Biotechnology Holdings achieved official laboratory accreditation for its CIZ1B lung cancer blood test in the United States. This milestone marks the firm's transition from the development phase to a commercialization phase.
Why it matters
The new test aims to improve early-stage detection rates for lung cancer, potentially saving lives through the use of small blood samples. The validation allows the firm to offer the biomarker test commercially within the United States.
The CIZ1B biomarker test achieved validation in a CLIA accredited laboratory in the United States. The test specifically requires only small quantities of blood to identify early-stage lung cancer.
The players
Cizzle Biotechnology Holdings
This biotechnology company is headquartered in York and focuses on the development of biomarker-based cancer diagnostic tools.
The details
Cizzle Biotechnology Holdings, based in York, utilizes specific licensing and laboratory partners in the United States to administer the diagnostic test. The company is now pivoting toward scaling its operations and negotiating further commercial agreements.
Timeline
The laboratory accreditation was achieved during the first half of 2026.
The Big Picture
The firm aligns with the CLIA laboratory accreditation process to ensure its diagnostic methodology meets national clinical standards. This step follows established regulatory protocols required for the entry of new diagnostic tools into the U.S. market.
The availability of a commercial blood test allows patients to utilize a less invasive method for early lung cancer screening. Individuals should consult their primary care physician to determine if this new diagnostic option is appropriate for their specific health profile.
The takeaway
The successful commercialization of this biomarker test represents a shift toward more accessible diagnostic tools for early lung cancer detection. Patients are encouraged to track the availability of such screenings as the company expands its rollout across North America.
Further reading
For more on diagnostic advancements, explore the latest Cancer developments.
Source note: This article includes information reported by Yorkshire Post.
Live Poll
Would you regularly undergo a blood test if it could detect early-stage lung cancer?
